Al-Azzam Sayer I, Alzoubi Karem H, Abeeleh Jaafar Abu, Mhaidat Nizar M, Abu-Abeeleh Mahmoud
Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
Clin Pharmacol. 2013;5:33-8. doi: 10.2147/CPAA.S42496. Epub 2013 Feb 20.
Statins are commonly used antihyperlipidemic agents, with anti-inflammatory and immunomodulatory properties that are thought to account for a significant portion of their ability to protect against atherosclerosis and cardiovascular disease. Vaspin, a visceral adipose tissue-derived serine protease inhibitor, is an emerging adipokine with important insulin-sensitizing, cardioprotective, and antiatherosclerotic properties in patients with diabetes. In this randomized controlled clinical trial, we evaluated the effect of statin therapy on vaspin levels in patients with type 2 diabetes mellitus.
Patients were divided into two groups, ie, those receiving simvastatin (study group, n = 33), and those who did not (control group, n = 29). Patient data, blood biochemistry, and vaspin levels were recorded at the beginning of the study (baseline) and after 8 weeks (end of the study).
After 8 weeks of treatment, vaspin levels were increased in patients treated with simvastatin (504.58 ± 203.07 pg/mL at baseline versus 629.15 ± 68.39 pg/mL after 8 weeks, P < 0.01), but not in patients who were not treated with simvastatin (613.33 ± 357.53 pg/mL at baseline versus 582.37 ± 84.63 pg/mL after 8 weeks, P > 0.05). In addition, the lipid-lowering effect of simvastatin was reflected in a statistically significant reduction in total cholesterol in the study group (220.75 ± 55.66 mg/dL at baseline versus 201.90 ± 53.65 mg/dL after 8 weeks P < 0.01) but not in the control group (214.24 ± 47.2 mg/dL at baseline versus 215.72 ± 43.65 mg/dL after 8 weeks, P > 0.05) and in a statistically significant reduction in triglyceride levels in the study group (265.8 ± 210.41 mg/dL at baseline versus 223.03 ± 178.67 mg/dL after 8 weeks, P < 0.05) but not in the control group (225.44 ± 115.13 mg/dL at baseline versus 215.58 ± 110.2 mg/dL after 8 weeks, P > 0.05). Mean vaspin levels were significantly higher in the study group than in the control group.
These results indicate that statin therapy increases plasma vaspin levels in addition to having a lipid-lowering effect. This could be a mechanism underlying the pleiotropic effects seen with statins, including their cardioprotective and antiatherosclerotic effects.
他汀类药物是常用的抗高脂血症药物，具有抗炎和免疫调节特性，被认为在预防动脉粥样硬化和心血管疾病的能力中占很大一部分。内脏脂肪组织衍生的丝氨酸蛋白酶抑制剂内脏脂肪素是一种新兴的脂肪因子，对糖尿病患者具有重要的胰岛素增敏、心脏保护和抗动脉粥样硬化特性。在这项随机对照临床试验中，我们评估了他汀类药物治疗对2型糖尿病患者内脏脂肪素水平的影响。
患者分为两组，即接受辛伐他汀治疗的患者（研究组，n = 33）和未接受治疗的患者（对照组，n = 29）。在研究开始时（基线）和8周后（研究结束时）记录患者数据、血液生化指标和内脏脂肪素水平。
治疗8周后，接受辛伐他汀治疗的患者内脏脂肪素水平升高（基线时为504.58±203.07 pg/mL，8周后为629.15±68.39 pg/mL，P < 0.01），而未接受辛伐他汀治疗的患者内脏脂肪素水平未升高（基线时为613.33±357.53 pg/mL，8周后为582.37±84.63 pg/mL，P > 0.05）。此外，辛伐他汀的降脂作用体现在研究组总胆固醇有统计学意义的降低（基线时为220.75±55.66 mg/dL，8周后为201.90±53.65 mg/dL，P < 0.01），而对照组无变化（基线时为214.24±47.2 mg/dL，8周后为215.72±43.65 mg/dL，P > 0.05）；研究组甘油三酯水平有统计学意义的降低（基线时为265.8±210.41 mg/dL，8周后为223.03±178.67 mg/dL，P < 0.05），而对照组无变化（基线时为225.44±115.13 mg/dL，8周后为215.58±110.2 mg/dL，P > 0.05）。研究组的平均内脏脂肪素水平显著高于对照组。
这些结果表明，他汀类药物治疗除具有降脂作用外，还可提高血浆内脏脂肪素水平。这可能是他汀类药物多效性作用的潜在机制，包括其心脏保护和抗动脉粥样硬化作用。
